Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME

被引：0

作者：

Inzucchi, S. E. ^{[1
]}

Khunti, K. ^{[2
]}

Fitchett, D. H. ^{[3
]}

Wanner, C. ^{[4
]}

Mattheus, M. ^{[5
]}

George, J. T. ^{[6
]}

Ofstad, A. P. ^{[7
]}

Zinman, B. ^{[8
]}

机构：

[1] Yale Sch Med, Sect Endocrinol, New Haven, CT USA

[2] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England

[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[4] Wurzburg Univ Clin, Div Nephrol, Wurzburg, Germany

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Boehringer Ingelheim Norway KS, Asker, Norway

[8] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷

关键词：

Sodium glucose co-transport inhibitor 2; Cardioprotection; Heart failure;

D O I：

10.1016/j.metabol.2019.12.071

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：1

共 50 条

[21] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
Ridderstrale, M.
Fitchett, D.
Kis, S. Giljanovic
Woerle, H. J.
Mattheus, M.
Zinman, B.
Inzucchi, S.
EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
[22] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
Lund, S. S.
McGuire, D. K.
Zinman, B.
Inzucchi, S. E.
Anker, S. D.
Wanner, C.
Kaspers, S.
George, J. T.
Elsasser, U.
Woerle, H. J.
Fitchett, D.
DIABETOLOGIA, 2018, 61 : S324 - S325
[23] Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
Udell, J.
Zinman, B.
Wanner, C.
Von Eynatten, M.
George, J. T.
Zwiener, I.
Lund, S. S.
Hantel, S.
Fitchett, D.
EUROPEAN HEART JOURNAL, 2019, 40 : 55 - 55
[24] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
Bernard Zinman
Silvio E. Inzucchi
Christoph Wanner
Uwe Hehnke
Jyothis T. George
Odd Erik Johansen
David Fitchett
Diabetologia, 2018, 61 : 1522 - 1527
[25] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
McGuire, D. K.
Zinman, B.
Inzucchi, S. E.
Anker, S. D.
Wanner, C.
Kaspers, S.
George, J. T.
Elsasser, U.
Woerle, H. J.
Lund, S. S.
Fitchett, D.
EUROPEAN HEART JOURNAL, 2018, 39 : 1091 - 1091
[26] Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Coleman, Ruth L.
Gray, Alastair M.
Broedl, Uli C.
Fitchett, David
George, Jyothis T.
Woerle, Hans J.
Zinman, Bernard
Holman, Rury R.
DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1151 - 1156
[27] EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
Perkovic, Vlado
Levin, Adeera
Wheeler, David
Koitka-Weber, Audrey
Mattheus, Michaela
George, Jyothis
von Eynatten, Maximilian
Wanner, Christoph
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 12 - 12
[28] EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction
Aroda, Vanita R.
Sabatine, Marc S.
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : 932 - 933
[29] Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME
Schnee, J.
Inzucchi, S. E.
Zinman, B.
McGinniss, J.
George, J. T.
Fitchett, D.
DIABETOLOGIA, 2017, 60 : S85 - S86
[30] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
Verma, Subodh
Leiter, Lawrence A.
Zinman, Bernard
Sharma, Abhinav
Mattheus, Michaela
Fitchett, David
George, Jyothis
Ofstad, Anne Pernille
Kosiborod, Mikhail N.
Wanner, Christoph
Inzucchi, Silvio E.
ESC HEART FAILURE, 2021, 8 (04): : 2603 - 2607

← 1 2 3 4 5 →